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PERSPECTIVES IN RENAL MEDICINE
Renal angiomyolipomata
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Renal angiomyolipomata. Renal angiomyolipomata can exist
as an imaging curiosity or represent a life-threatening condi-
tion. There are likely over 10 million people world-wide who
have a renal angiomyolipomata and approximately one tenth
of these people also have tuberous sclerosis complex. The op-
timum treatment of angiomyolipomata is focused on sparing
renal tissue and has included no intervention, both total and
partial nephrectomy, and embolization. As basic science inves-
tigation into the biology of angiomyolipomata progresses, there
is even hope for successful drug therapy. Because these renal
lesions can be associated with other organ system dysfunction,
a number of medical specialists become involved in the care
of affected patients. The purpose of this article is to update the
nephrologist on the molecular understanding of renal angiomy-
olipomata and for the possibilities of pharmacologic therapy in
the future.
Renal angiomyolipomata exhibit an extremely broad
disease spectrum, from merely an imaging curiosity to
a life-threatening condition. Using the estimated world
population of over six billion individuals [1], the gen-
der distribution and frequency of angiomyolipomata [2],
there are over 10 million people world-wide with renal
angiomyolipomata and approximately one tenth of these
also have tuberous sclerosis complex. The optimum treat-
ment of angiomyolipomata has logically focused on spar-
ing renal tissue. It has included no intervention, both total
and partial nephrectomy, and embolization. As basic sci-
ence investigation into the biology of angiomyolipomata
progresses, there is even hope for successful drug ther-
apy, at least in tuberous sclerosis complex and lymphan-
gioleiomyomatosis. Because these renal lesions can be
associated with other organ system dysfunction, a num-
ber of medical specialists become involved in the care of
affected patients. The purpose of this article is to update
the nephrologist on the clinical and pathologic features of
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this lesion, with special emphasis on the molecular under-
standing of renal angiomyolipomata in tuberous sclero-
sis and lymphangioleiomyomatosis. Recent basic science
discoveries in these diseases offer hope for pharmaco-
logic therapy in the future.
DISEASE FREQUENCY AND ASSOCIATED
CONDITIONS
Grawitz [3], in 1900, first used the term renal angiomy-
olipoma to describe a large renal tumor comprised of fat,
muscle, and blood vessels. In a study of 8501 autopsies in
which there were no stigmata of tuberous sclerosis com-
plex recognized, Hajdu and Foote [4] found two males
and 25 females with angiomyolipomata, resulting in fre-
quencies of 0.02% and 0.29% of the total population, re-
spectively. These data compare favorably to the imaging
studies by Fujii et al [2] involving 12,970 male and 4971
female Japanese that identified angiomyolipomata in 13
(0.1%) males and 11 (0.22%) females. The difference in
frequency in males in these two studies likely reflects the
small numbers of males in each. The consistent increased
frequency in females may be due in part to hormonal dif-
ferences. Angiomyolipomata often express receptors for
both estrogen and progesterone [5].
ASSOCIATED CONDITIONS
Although often found incidentally, renal angiomy-
olipomata can be associated with two conditions affecting
other organ systems: tuberous sclerosis complex (TSC)
and sporadic lymphangioleiomyomatosis (LAM). This
review focuses on the angiomyolipomata in these dis-
eases. Twenty years after Bourneville [6] described TSC,
he and Brissaud [7] noted renal angiomyolipoma in pa-
tients with TSC. TSC actually has three renal phenotypes,
including angiomyolipomata, cysts, and carcinoma. These
lesions may occur individually or coexist (Fig. 1). Growth
of angiomyolipomata in patients with TSC is often first
detected during childhood [8] and continues into adult-
hood [9, 10]. An autopsy study found that 67% of TSC
patients have angiomyolipomata [11]. The frequency of
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angiomyolipoma varies with the age of the population
being studied; the frequency is higher in older subjects.
There are two morbidities associated with renal
angiomyolipomata. The first and more dramatic is
Wunderlich syndrome [12], retroperitoneal hemorrhage
originating in the angiomyolipoma. Angiomyolipomata,
as they enlarge, frequently develop both micro- and
macroaneurysms which can rupture [13, 14]. Patients with
this sudden, painful, and often life-threatening event are
most often first seen in the emergency department. Up to
20% of patients with such hemorrhages present in shock
[15]. With such a presentation, the treatment may be a to-
tal nephrectomy. This approach complicates the patient’s
long-term care. Angiomyolipomata associated with TSC
are bilateral and a nephrectomy would result in a signif-
icant loss of functional renal tissue, thus hastening the
need for renal replacement therapy. The risk of hemor-
rhage from renal angiomyolipomata has been reported
to be between 25% and 50% [16]. A population study
suggests that the cumulative risk of a hemorrhage is 18%
for females and 8% for males [17]. However, among a
clinic population of approximately 310 adult and pedi-
atric tuberous sclerosis complex patients in Cincinnati,
we have seen only nine cases of hemorrhage (∼3%). This
difference may be, at least in part, due to our aggres-
sive embolization program, population age differences or
length of follow-up. Although angiomyolipomata appear
to grow over time, and there is an association between
lesion size and hemorrhage [10, 18], bleeding is in fact
much more strongly associated with aneurysm formation
[19]. This, in part, explains why modest lesions and young
patients can still have substantial hemorrhages. The likely
scenario is that the larger aneurysms rupture and de-
compress into the retroperitoneal space or renal pelvis
(Fig. 2).
The second morbidity of renal angiomyolipomata is the
insidious encroachment of the angiomyolipoma on nor-
mal renal tissue, which may lead to renal failure [20, 21].
The precise incidence of end-stage renal disease (ESRD)
in the tuberous sclerosis population has not been well de-
fined, but European surveys suggest that approximately
1% of the TSC patient population with normal intellect
is receiving dialytic renal replacement therapy [20, 21],
leading to an estimate that over 30,000 TSC patients are
Fig. 1. Magnetic resonance (MR) imaging of the renal lesions of three
adult tuberous sclerosis complex (TSC) patients. (A) Fast spin echo in-
version recovery image demonstrates the lesion in the upper pole of
the right kidney by the contrast with the normal kidney. (B) Fast spin
echo T2-weighted image demonstrating the bright signal intensity of
lesions compatible with a cyst (see arrow) and dark signal intensity le-
sion compatible with fat (asterisk). Both cystic and angiomyolipomata
can be identified in both kidneys. (C) T1-weighted image with two le-
sions with increased signal intensity (arrows) similar to subcutaneous
fat (asterisk), compatible with large angiomyolipoma.
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Fig. 2. Angiography of the right kidney revealing angiomyolipoma of
the upper pole with aneurysms. The largest is marked with the arrow.
on dialysis worldwide. Shepherd et al [22] examined death
certificates for patients in their TSC clinic and found that
of 355 patients, 40 died as a result of their TSC, most com-
monly due to renal failure. These studies are helpful to
understand the scope of disease, though the actual num-
ber of patients with renal insufficiency and comorbidities
is unknown. The percentage of TSC patients develop-
ing ESRD because of polycystic kidney disease, multiple
interventions for hemorrhage, or replacement of renal
tissue by angiomyolipomata is unclear. Renal function
is often normal even in patients with apparently bilat-
eral confluent angiomyolipomata. Kidneys with a large
angiomyolipoma burden can still contribute significantly
to total renal function and the decision to undergo a
nephrectomy should be carefully balanced against the
loss of function (Fig. 3).
Approximately 35% of patients with TSC will have
renal cysts [23]. Although these lesions may be large, they
usually are not numerous and rarely cause problems. One
exception is the polycystic kidney disease phenotype, or
disease manifestation, of TSC, in which patients are at
risk for the same morbidities as patients with autosomal
polycystic kidney disease (Fig. 4). This phenotype is due
to joint disruption of the TSC2 gene and the very closely
adjacent PKD1 gene resulting in both TSC and polycystic
kidney disease [24, 25]. Even patients with the polycystic
phenotype can develop angiomyolipomata.
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Fig. 3. Demonstration of preserved function despite large angiomy-
olipoma burden in an adult. (A) Magnetic resonance imaging (MRI)
scan demonstrating significant involvement in the both kidneys. (B) De-
spite a large angiomyolipoma burden, the 99m-technetium diethylene-
triamine pentaactetic acid (99mTc-DTPA) scan demonstrates function
in both kidneys. The glomerular filtration rate for this patient was ap-
proximately 95 mL/min/1.73 m2, and the right kidney contributed 44%
of the total function. The functional kidney tissue is circled using a
dotted line.
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Fig. 4. Polycystic renal variety of tuberous sclerosis complex (TSC) in
a child. (A) Renal ultrasound revealing significant polycystic disease.
(B) Renal scan revealing functional renal tissue between the cysts. The
child had a normal glomerular filtration rate and well-controlled hyper-
tension.
Angiomyolipomata are also associated with LAM
(Fig. 5), a disease involving the pulmonary interstitium
which occurs almost exclusively in young females [26],
though its presence in a male has been reported [27]. Ap-
proximately 40% of female patients with TSC also de-
velop a cystic pulmonary disease consistent with LAM
[28–30]. However, the disease progression may be dif-
ferent from the sporadic form of the disease and only
approximately 1% of women with TSC develop clinical
symptoms [31].
LAM also occurs in patients without TSC (denoted as
sporadic LAM). This sporadic form is rare, less than 1000
affected women have been identified world-wide [32],
and 60% of these patients also have an angiomyolipoma
[11]. The angiomyolipoma histopathologic features seen
in sporadic LAM are identical with those found in TSC
[33].
Both TSC associated and sporadic LAM is charac-
terized by smooth muscle infiltration into the walls of
the alveoli and small airways. This can lead to cystic
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Fig. 5. Utility of computed tomography (CT) in lymphangioleiomy-
omatosis (LAM). (A) High resolution CT scan revealing cystic
parenchymal changes of LAM. (B) Renal CT scan demonstrating mul-
tiple lesions of –15 to –100 Hounsfield units, characteristic of fat.
degeneration of lung tissue, impaired gas exchange,
respiratory failure, and death. Progressive symptomatic
lung disease may occur in patients diagnosed with spo-
radic LAM and such progression likewise would be pre-
dicted to occur in women with TSC-associated LAM.
There is recent evidence that LAM may be caused by
metastases of angiomyolipoma cells to the lung [34, 35].
These cells express estrogen receptors [36], and this find-
ing has been used to help explain the gender bias in spo-
radic LAM as well as a rationale for a therapeutic trial of
progesterone [37].
CLASSIFICATION OF RENAL
ANGIOMYOLIPOMATA
Angiomyolipomata were originally thought by Fischer
[38] by to be an abnormal proliferation of the tissues that
are normally present in the kidney, and hence, he clas-
sified them as hamartomata. Dickinson et al [18] noted
that fat and smooth muscle are not normally found in the
renal parenchyma, and classified angiomyolipomata as
choristomata. As basic science investigation has better
defined these lesions, angiomyolipomata are best classi-
fied as neoplasia. This classification is supported by the
finding that these lesions arise from clonal expansion
based on nonrandom X chromosome inactivation [39]
and exhibit lymph node invasion [40, 41]. The perivas-
cular epithelioid cell has been implicated as the progeni-
tor for a family of neoplasms, including angiomyolipoma,
lymphangiomyoma, and clear cell tumors of the lung
and pancreas [42, 43]. These cells have been proposed
to differentiate into spindle-shaped cells with features of
adipose, smooth muscle, and eosinophilic and clear ep-
ithelioid cells. A feature of these perivascular epithelioid
cell–derived lesions is HMB-45 immunoreactivity; the
spindle and epithelioid cells often stain with anti-smooth
muscle actin while the fat cells stain with S-100 antibodies.
While most often described in the kidneys, angiomyolipo-
mata also have been identified in the liver [44], ovary [45],
fallopian tube [46], spermatic cord [47], palate [48], and
colon [49].
There are two basic types of angiomyolipoma. The
classic form contains vascular, smooth muscle, and adi-
pose tissue (Fig. 6). The contribution of each of these
components can vary from lesion to lesion in the same
kidney. The vascular component may be scant or may
dominate the lesion [50]. Five different types of vessels
within angiomyolipomata have recently been recognized
[51], some of which are deficient in elastic fibers [52].
The smooth muscle component can be limited to a small
amount cuffing the vasculature [53], or may be so ex-
tensive that imaging detects a solid mass devoid of fat
[54]. In classic angiomyolipomata, there can be patches
of smooth muscle cells that exhibit nuclear atypia with mi-
totic figures; despite these findings, such lesions typically
do not behave as a malignant lesion. There are only a few
case reports of sarcoma arising from an angiomyolipoma,
which has been termed malignant angiomyolipoma [55,
56]. Like the smooth muscle and vascular component, the
adipose element of angiomyolipomata can be variable.
Most often the fat component is made up of mature fat
tissue. Very rarely, renal angiomyolipomata can infiltrate
surrounding tissue [57].
The epithelioid variant of angiomyolipomata has re-
cently been described [58, 59]. These lesions have a large
component of epithelioid cells (Fig. 7). The epithelioid
cells may be polygonal with a slight degree of nuclear
atypia, or atypical and variable in size; these lesions may
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Fig. 6. Classic renal angiomyolipoma histology using hematoxylin and
eosin stain. Note the multiple thick-walled blood vessels, smooth muscle
cells, and fat cells.
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Fig. 8. Model for how tuberin and hamartin
regulate cell growth. Binding of ligands (such
as insulin) to cell surface tyrosine kinase re-
ceptors results in autophosphorylation of the
receptor, and docking of adaptor proteins and
phosphatidylinositol 3′-kinase (PI3K). Pro-
tein kinase B (PKB), also known as Akt, is
phosphorylated and activated, which in turn
phosphorylates tuberin. Tuberin dissociates
from hamartin, permitting phosphorylation
and activation of mammalian target of ra-
pamycin, or mTOR, by way of Rheb. Acti-
vated mTOR phosphorylates S6K and initi-
ation factor 4E binding protein (4E-BP), and
the kinase activity and release of the kinase ac-
tivity and release of translation initiation fac-
tor eIF-4E promote protein synthesis and cell
growth. Absence of tuberin permits constitu-
tive activation of S6K and 4E-BP, which pro-
vides a persistent and inappropriate stimulus
for growth (adapted in part from McManus
and Alessi [113]).
Fig. 7. Epithelioid renal angiomyolipoma histology using hematoxylin
and eosin stain. Note clear demarcation of normal renal tissue and the
polygonal epithelioid cells.
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exhibit significant mitotic activity. There are few or no ab-
normal vessels or fat cells in these lesions. Very aggressive
epithelioid angiomyolipomata have been reported, some-
times as HMB-45 antibody–positive malignant angiomy-
olipomata, and these lesions can recur after resection and
can be fatal [59–61]. Based on further analysis of these
cases as well as other studies, Eble [62] postulates that the
epithelioid renal angiomyolipomata are more aggressive
than the more typical angiomyolipoma.
ASSOCIATION WITH CANCER
Other neoplasms appear to be associated with an-
giomyolipomata. These include oncocytomas and renal
cell carcinomas. Oncocytoma, a benign, renal epithe-
lial cell neoplasm, consists of polygonal cells with abun-
dant, finely granular cytoplasm filled with mitochondria.
These lesions make up about 5% of surgically resected
renal neoplasms [63], and may be more common in TSC
[64]. The lesions histochemically label with epithelial cell
markers but fail to express vimentin and are HBM-45
nonreactive [63, 65]. Another lesion, which histologically
appears to be an oncocytoma, but lacking epithelial cell
markers and is HMB-45–positive, has been described as
an oncocytoma-like angiomyolipoma [63].
The concurrence of renal cell carcinoma and angiomy-
olipoma appears to be rare. Jimenez et al [64] identified
only 52 cases in the literature, and was the uncertain
whether patients with TSC were at increased risk for a
renal cell neoplasm compared to the general population.
Pea et al [66] note that the epithelioid variant of angiomy-
olipoma closely simulates renal cell carcinoma, making it
difficult to determine the real frequency of authentic re-
nal cell carcinomas among the reported cases in the liter-
ature. The epithelioid variety can also exhibit a clear cell
histologic appearance [67]. A distinction between renal
cell carcinoma and angiomyolipomata has been made in
part based on the immunohistochemical findings. Renal
cell carcinoma exhibit keratin but lack HMB-45 staining,
while the epithelioid variety will demonstrate the reverse
[66]. Tello et al [68] have performed a meta-analysis and
failed to find a statistical relationship between TSC and
renal cell carcinoma. However, the occurrence of renal
cell carcinoma in children and young adults with TSC
[69], including several reports of multifocal renal cell car-
cinoma in children with TSC under the age of 10 years,
would indicate that an association does exist.
Two interesting observations may offer insight into
the link between cancer and angiomyolipomata. First
is that renal carcinoma in TSC has been seen in as-
sociation with renal cystic disease [69], analogous to
carcinoma associated with other (non-TSC) renal cystic
diseases [70]. Perhaps the carcinoma risk is linked to the
renal cystic disease and not to the angiomyolipomata. The
second observation is that angiomyolipoma have been
noted to have other chromosomal abnormalities, sug-
gesting the possibility that, in some lesions, the specific
secondary chromosomal rearrangement may contribute
to malignant progression [69]. Although the relationship
of tuberous sclerosis and renal cell carcinoma is uncer-
tain, angiomyolipoma can act aggressively, and can rarely
undergo malignant transformation. Therefore, angiomy-
olipoma should be closely monitored to avoid undue pa-
tient risk [71].
GENETICS OF ANGIOMYOLIPOMATA
Angiomyolipomata develop from clonal expansion of
a cell that has acquired proliferative autonomy [39, 72,
73]. Genetic linkage analyses of families with TSC have
lead to the discovery of two genes that are associated with
angiomyolipomata. These genes are TSC1, found at chro-
mosome 9q34, and TSC2 found at 16p13 [74]. Analysis of
sporadic angiomyolipomata has likewise revealed an as-
sociation with TSC2 [75]. In a study of 130 sporadic (i.e.,
nonfamilial) TSC cases, 68% had germline TSC2 muta-
tions, 22% had no identifiable mutation, and 10% had
germline TSC1 mutations [76, 77].
Angiomyolipomata, TSC, and LAM related as well as
at least some unrelated lesions, appear to be the conse-
quence of somatic mutagenesis. The molecular pathogen-
esis of an angiomyolipoma associated with TSC involves
the inheritance of a mutant allele compounded by a so-
matic mutation that results in a loss of heterozygosity
(LOH). Patients with TSC have a germline mutation in
the copy of the TSC1 or TSC2 gene that either arose
sporadically or was inherited from the affected parent.
Cells are heterozygous with one abnormal and one func-
tional gene. The single normal allele is sufficient to en-
sure normal cell proliferation and organ development.
However, sporadic somatic mutations of the wild-type
allele in vulnerable tissues lead to a variable number of
tumors. The cells of the lesion appear to be either ho-
mozygous or hemizygous for the mutant allele because
they exhibit LOH at the involve TSC locus. The role of
somatic mutagenesis in TSC has been clearly established
[75, 78–80]. LOH of TSC2 was also noted by Smolarek
et al [81] in 7 of 13 angiomyolipomata from women with
sporadic LAM, and specific TSC2 mutations were identi-
fied [82]. In this sporadic form of disease, approximately
half of the women also have renal angiomyolipomata.
Angiomyolipomata not associated with sporadic LAM
or TSC have also been reported to exhibit LOH at chro-
mosome 16p13. Martignoni et al [83] studied epithelioid
angiomyolipoma tissue from three patients without TSC
or LAM, and found LOH at chromosome 16p13 in one
of these patients. These findings raise the possibility that
least some of the angiomyolipomata not associated with
LAM or TSC also may be associated with mutations in
the TSC2 gene. These germline and somatic mutations
930 Bissler and Kingswood: Renal angiomyolipomata
silence the locus and are an example of the two-hit hy-
pothesis Knudson [84] proposed for retinoblastoma.
The origin of LAM cells is also controversial, but three
lines of evidence suggest that angiomyolipoma smooth
muscle cells metastasize to the lung, where they prolif-
erate and progressively replace the normal lung tissue.
First, TSC mutations in LAM cells and angiomyolipoma
cells from sporadic LAM patients, who do not have germ
line mutations in TSC genes, are identical, suggesting a
common origin [82]. Second, TSC patients with LAM are
more likely to have large or problematic angiomyolipo-
mata, which are potentially more likely to seed the lung
[28]. Studies from the University of Cincinnati and else-
where have revealed that pulmonary cystic changes con-
sistent with LAM are present in up to 40% of women
with TSC [28–30]. Third, a recent genetic analysis of
recurrent LAM lesions in a lung allograft after lung trans-
plantation proved the recipient origin of smooth mus-
cle cells in the lesion [34]. LAM cells isolated from the
lung and angiomyolipomata cells share many genotypic
and phenotypic characteristics, including genetic muta-
tions in TSC genes and staining with specific markers,
including the melanocyte-derived monoclonal antibody
HMB-45 and to smooth muscle actin. Because of their
biologic similarities and growing evidence that the lung
lesion in TSC may arise from angiomyolipomata, we pos-
tulate that strategies that effectively control the growth of
angiomyolipoma cells in the kidney may also control the
growth of LAM cells in the lung. As explained above, an
important feature of the cells in LAM and angiomyolipo-
mata is that, in addition to an inherited mutation in one
copy of their TSC1 or TSC2 genes, they have undergone a
second somatic mutation that has disabled the wild-type
gene. This second mutation produces a deficiency of ei-
ther hamartin or tuberin, respectively. Insight into how
this genetic difference between angiomyolipoma and nor-
mal cells leads to disease expression has only recently be-
come available (for review, see [85]). Genetic analysis of
Drosophila homologues Tsc11 and Tsc2 helped identify
a role for hamartin and tuberin in cell organ morphology.
Initially described by Farrus and Garcia-Bellido in 1976,
the fruit fly gigas was found to have a mutation in the
human homologue for Tsc2 by Ito and Rubin [86]. Fur-
ther work in this experimental system revealed that the
Tsc1 and Tsc2 loci played a role in the regulation of cell
and organ size. Homozygous inactivation of either Tsc1 or
Tsc2 had identical phenotypic result, an increase in organ
size that was due to an increase in cell size. Conversely,
a simultaneous increase in the expression from both the
Tsc1 and Tsc2 loci resulted in the opposite phenotype.
Because cell size regulation had been associated with the
PI3K-Akt-S6K pathway, genetic studies designed to elu-
cidate the possible position of the Tsc1 and Tsc2 gene
product in the pathway have been undertaken by several
investigators.
Cultured mammalian cells lacking tuberin or hamartin
constituently produce a high level of S6K and 4EBP1 [87–
89]. Treatment of these cells with rapamycin results in a
rapid dephosphorylation and these treated cells become
resistant to amino acid starvation [90]. These findings are
consistent with the activation of the mammalian phos-
phatidylinositol 3′-kinase (PI3K)-Akt-S6K pathway and
the pivotal role for mTOR in the absence of hamartin or
tuberin (Fig. 8).
CLINICAL MANAGEMENT
Angiomyolipomata are most often identified by imag-
ing studies done to work up suspected disease, including
hemorrhage, or as an incidental finding. Although these
lesions can be quite large when identified, they typically
are rather slow growing, and their large size attained over
a longer time. Such predictable growth allows the clini-
cian to identify a malignant lesion by a sudden increase
in size, and underscores the value of periodic imaging.
Large nonmalignant lesions can arise because of slow,
continuous growth, or by the coalescence of multiple ad-
jacent lesions. Lesions typically contain variable amounts
of vascular, smooth muscle, and adipose elements. The
composition is quite variable and they may also be com-
posed of mostly solid elements such as smooth muscle.
The epithelioid variety also contains very little or no fat
nor the typical dysplastic vascular elements. The decision
to biopsy such lesions is based on unusual growth and
imaging characteristics. The risk of spontaneous hemor-
rhage, associated with aneurismal rupture [19] does not,
by itself, increase the risk of bleeding following biopsy.
The bleeding risk with biopsy is likely to be somewhat
increased based on the dysplastic nature of the angiomy-
olipomata vasculature, but such is rarely the case in the
epithelioid variety, and the vascular portion of the lesion
can be crudely assessed by the degree of enhancement on
imaging studies. In cases where the diagnosis is not clear,
biopsy can guide therapy [91].
The primary reason to intervene in patients with re-
nal angiomyolipomata has been to alleviate symptoms
such as pain or hemorrhage, or to establish a diagnosis
when the lesion has a low fat content that raises the sus-
picion of a carcinoma. Factors that affect the decision to
intervene, as well as the method include the presence of
symptoms, lesion size, visible aneurysms, renal reserve,
pregnancy plans, patient occupation, activity, and com-
pliance. The recent urological literature has embraced a
renal sparing approach for angiomyolipomata [92]. Key
to the long-term outcome of patients with multiple re-
nal angiomyolipomata is the preservation of renal func-
tion. Current clinical measurements of renal function
fail to measure renal reserve. This concept is critical be-
cause many case reports regarding nephron-sparing surg-
eries use normal serum creatinine values to indicate the
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Fig. 9. Renal aneurysm in an angiomy-
olipoma. (A) Single proton gradient reso-
nance (SPGR) sequence magnetic resonance
imaging (MRI) revealing a 1.1 cm bright sig-
nal intensity in the lower pole of the left
kidney compatible with a dilated or ectatic
vessel or an aneurysm. (B) Angiography
clearly showing the large aneurysm. (C)
Three-dimensional reconstruction of vascula-
ture to aid in embolization procedure. (D)
Postembolization angiography showing the
lack of blood flow to the vasculature, and the
coils in place.
Fig. 10. Renal ultrasound revealing multiple angiomyolipomata in a
child. Because these lesions typically contain a significant amount of
adipose tissue, they are bright on ultrasound.
absence of renal damage [93, 94]. Because renal angiomy-
olipomata continue to grow, albeit slowly, indications for
a total nephrectomy are limited and include a nonfunc-
tioning kidney resulting in uncontrolled hypertension, lo-
cal tissue invasion [95], tumor in the renal vein [96, 97],
or very strong evidence of malignancy.
Partial or nephron-sparing nephrectomies run the risk
of significant hemorrhage, and therefore should be un-
dertaken only if unequivocally indicated. A suitable al-
ternative to such invasive procedures is embolization
(Fig. 9). Embolization, first used to treat angiomyolipo-
mata approximately 20 years ago, obliterates the blood
supply to the angiomyolipomata and thus reduces the
risk of hemorrhage [98]. Embolization also has signifi-
cant side effects. Following embolization, approximately
85% of patients develop post-embolization syndrome, in-
cluding significant fever and pain [16, 98–109]. The use
of glucocorticoids can ameliorate this complication [14].
Embolization is the preferred therapy and appears to be
the most successful nephron-sparing procedure [92].
Although embolization and surgical therapies can suc-
cessfully treat solitary lesions, the much more vexing clin-
ical problem of coalescent renal angiomyolipomata that
replace renal parenchyma has remained largely unad-
dressed (Fig. 10). When bleeding occurs in this circum-
stance, it can be impossible to identify which lesion is the
source.
ANIMAL MODELS OF ANGIOMYOLIPOMATA
Data from experimental animals and humans confirm
the in vivo relevance of the Akt signaling pathways in
tuberous sclerosis. Although not perfect mimics of the
human disease, tuberin and hamartin heterozygous null
mice develop several renal and hepatic neoplasms that
are thought to be potential models for tuberous sclerosis
[88, 110]. The hepatic tumors are rich in smooth mus-
cle and are HMB-45–positive, consistent with the histo-
logical and immunohistochemical characteristics of LAM
and angiomyolipoma lesions from patients. Female mice
die from fatal hemorrhage into the liver lesion after 1 year
of age, suggesting an influence of estrogen that also mim-
ics human LAM. Most encouraging is that S6K is consti-
tutively activated in the lesions of the TSC1+/− mice, and
rapamycin quenches both the S6K phosphorylation and
inappropriate cell growth in murine embryonic fibrob-
lasts isolated from the animals [88]. Several investiga-
tors have demonstrated that rapamycin causes shrinkage
of renal tumors in mouse [111] and rat [112] TSC mod-
els. The shrinkage was associated with inhibition of S6K
phosphorylation and abundant apoptosis. S6K is constitu-
tively active in LAM lesions, angiomyolipomata [51], and
LAM cell models derived from humans and the Eker rat,
and rapamycin can suppress inappropriate cell growth
and S6K activation [87].
CONCLUSIONS AND FUTURE DIRECTIONS
Renal angiomyolipomata are far from uncommon, and
a great deal of progress has been made in understanding
the genetics and biochemistry of this lesion, especially as
it pertains to diseases like TSC and LAM. The optimum
treatment of angiomyolipomata continues to be focused
on sparing renal tissue. Initial published preclinical exper-
imentation as well as ongoing work support the possibil-
ity that pharmacologic therapies may become available.
Human trials to evaluate the utility of rapamycin in the
treatment of renal angiomyolipoma associated with TSC
and LAM are already underway. Should such therapies
have efficacy, the discipline of nephrology that already
has experience with drugs like rapamycin will likely play
a dominant role in the care of these patients.
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